Insulin Degludec (new ultra-long acting Insulin) approved by FDA after much deliberation!!

Further to the last tweet of “watch the space’ on FDA’s deliberations on the previously EMA approved Insulin Degludec, it was good to see the two agencies agree on the approval (despite some CV risk concerns raised). Does it really offer the benefit is really to be seen in practice mainly as the ‘FDA staff reviewers had suggested degludec may offer no strong advantage over other drugs in avoiding hypoglycemia’!

The true potential for use may be point of debate as splitting the dose of current long-acting insulins may still be a attractive choice taking into account a few of them may be coming to the end of their patent period.